Navigation Links
Pufferfish neurotoxin may serve as treatment for cancer therapy related pain
Date:6/26/2013

HACKENSACK, N.J. (June 26, 2013)- Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain. The active ingredient for the treatment is Tetrodotoxin, a neurotoxin found in pufferfish.

"Chemotherapy-induced neuropathic pain is a serious debilitating condition that occurs in over 40 percent of patients receiving chemotherapy," said Principal Investigator Samuel Goldlust, M.D., Co-Chief of the Brain and Spine Institute at John Theurer Cancer Center. "Tetrodotoxin has been found to be 3,000 times more potent than morphine without the negative side effects of opioids."

Caused by damage to neurons in the peripheral nervous system, chemotherapy-induced neuropathic pain is one of the most common reasons that cancer patients stop their treatment early, negatively affecting patient outcomes. For some patients, the symptoms persist after chemotherapy for months, years, or even indefinitely.

Until recently, chemotherapy-induced neuropathic pain, was treated primarily with opioids, anti-depressants or drugs primarily used to treat seizures. Scientists have learned more recently of the importance of sodium channels in the conduction of pain signals from peripheral nerves to the brain. Derived from a neurotoxin found in pufferfish, Tetrodotoxin targets sodium channels in the patient's peripheral nervous system. By blocking the sodium channels, Tetrodotoxin limits the conduction of pain signals to the central nervous system, offering relief from pain related to damage caused by chemotherapy.

Many species of marine pufferfish contain a large amount of Tetrodotoxin in their skin and tissues as an evolutionary adaptation to reduce predation. The dose used in this clinical trial needed for pain relief is approximately 300 times less than the total found in one fish.

"WEX is committed to developing a new class of non-opioid analgesics," said Mr. Walter Korz, VP, & General Manager of WEX Pharmaceuticals. "We are honored to have an institution such as John Theurer Cancer Center at HackensackUMC participating with Dr. Goldlust serving as Principal Investigator for this groundbreaking multicenter phase II clinical trial using Terodotoxin."

"Novel approaches to treatment are accelerating cancer care at an unprecedented rate," said Andre Goy M.D., M.S., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "We believe it is important that our researchers are actively involved in shaping the future of cancer care through clinical trials such as this one."

"Clinical trials allow us to continue offering the most advanced treatments options to our patients to improve outcomes and quality of life," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates, LLC.


'/>"/>

Contact: Jon Byington
jon.byington@porternovelli.com
212-601-8208
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. MS researchers determine that brain reserve independently protects against cognitive decline in MS
2. University of New England and Partners Celebrate Opening of Portland Community Health Center at Riverton June 20 for Underserved Populations
3. Effective Environmental Services Launch New Websites to Serve Customers
4. Allsup Observes National HIV Testing Day June 27
5. Merrill DataSite Releases New Comments: Cash Reserves and M&A Options
6. New Water Select® Showerhead Valve Conserves Water & Saves Money
7. On The Road to Better Health – Newark Residents to Be Served by New Mobile Health Center
8. PD-like sleep and motor problems observed in α-synuclein mutant mice
9. Fuseideas Expands to Serve Midwest Clients
10. Allsup Observes National Disability Professionals Week – June 10-14
11. Newport Board Group, a National Business Advisory Firm of CEOs That Serves the Middle Market, Issues Guidance for Companies Considering a Sale in 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
Breaking Medicine Technology: